Q-omics provides the consensus-scored TMC3 profile across patient tissues and cancer cell-line models. TMC3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMC3 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, TMC3 RNA expression shows 16,840 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, STAD, and TGCT as cancer lineages where TMC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMC3 survival associations across molecular data types. TMC3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMC3 RNA expression–survival associations across cancer types. High TMC3 expression shows unfavorable associations in MESO, KIRC and KICH, but favorable associations in BRCA, PAAD and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMC3 RNA expression.
This table summarizes TMC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMC3 shows lower tumor expression in STAD, KIRC, KICH and UCEC and higher tumor expression in HNSC and THCA. The STAD box plot shows higher TMC3 RNA expression in normal versus tumor tissue (log2 FC = −0.218, t-test p = .006).
This table shows molecular features associated with TMC3 in patient tissues and cancer cell lines. In patient samples, TMC3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
